HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ARMITAGE, J.
Right arrow Articles by COLLINS, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ARMITAGE, J.
Right arrow Articles by COLLINS, R.
Heart 2000;84:357-360 ( October )

Editorial

Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials

The first 150 words of the full text of this article appear below.

Diabetes mellitus contributes substantially to the global burden of disease, with an estimated 100 million people affected worldwide, and its prevalence is increasing rapidly.1 Macrovascular complications are among the chief causes of major morbidity in people with diabetes, and most of their deaths are attributed to cardiovascular causes.2 3 In type 2 ("non-insulin dependent") diabetes, blood triglyceride concentrations tend to be raised and high density lipoprotein (HDL) cholesterol concentrations reduced even with good metabolic control, whereas a similar pattern tends to emerge in type 1 ("insulin dependent") diabetes mellitus only when glycaemic control is poor.4 5 Typically in both type 1 and type 2 diabetes, however, blood concentrations of total and low density lipoprotein (LDL) cholesterol are similar to those in the general population. This may have contributed to the belief that LDL cholesterol is of little relevance to the risk of cardiovascular disease in diabetes4 6 and, apart from those with pronounced dyslipidaemia or pre-existing coronary heart . . . [Full text of this article]


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
F.D.R. Hobbs
Guidelines and management of global risk: the European perspective
Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C5 - C14.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
D.J. Betteridge
Treating dyslipidaemia in the patient with type 2 diabetes
Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C28 - C33.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
L. M. Prisant
Clinical Trials and Lipid Guidelines for Type II Diabetes
J. Clin. Pharmacol., April 1, 2004; 44(4): 423 - 430.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. P. Wright, R. N. Doughty, A. Pearl, G. D. Gamble, G. A. Whalley, H. J. Walsh, G. Gordon, W. Bagg, H. Oxenham, T. Yandle, et al.
Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial
J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1793 - 1800.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 BMJ Publishing Group Ltd & British Cardiovascular Society